Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is currently conducting a Korea Post Marketing Surveillance (PMS) Study of Vizimpro, officially titled ‘A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro®’. The study aims to assess the effectiveness and safety of Vizimpro, a drug approved for the treatment of EGFR NSCLC 1L in Korea, under general clinical practice conditions. This surveillance is crucial to identify any potential issues post-marketing.
The intervention being tested is Vizimpro, a drug designed to treat patients with EGFR NSCLC 1L. It is administered to patients as per the local label in routine clinical practice.
The study is observational and follows a prospective, case-only model. It does not involve any allocation or masking, focusing solely on observing the outcomes of patients treated with Vizimpro in a real-world setting.
The study commenced on March 7, 2021, and is currently recruiting participants. The last update was submitted on July 8, 2025. These dates are significant as they mark the progress and ongoing nature of the study, which is essential for investors tracking the development of Vizimpro in the market.
This study update could potentially influence Pfizer’s stock performance positively, as successful post-marketing surveillance can enhance investor confidence in Vizimpro’s market viability. It also positions Pfizer competitively within the pharmaceutical industry, particularly in the oncology sector.
The study is ongoing, and further details are available on the ClinicalTrials portal.